[1]余海 徐晓娟 沈霖△ 谢晶 杨艳萍 帅波 周丕琪.青娥丸对绝经后骨质疏松症患者骨密度、骨转换 标志物及骨桥蛋白的影响[J].中国中医骨伤科杂志,2016,24(01):21-23.
　YU Hai XU Xiaojuan SHEN Lin XIE Jing YANG Yanping SHUAI Bo ZHOU Piqi.The Effect of Qing'e Pill on BMD,Bone Metabolic and OPN in Patients with Postmenopausal Osteoporosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2016,24(01):21-23.
点击复制

青娥丸对绝经后骨质疏松症患者骨密度、骨转换 标志物及骨桥蛋白的影响
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第24卷
期数:
2016年01期
页码:
21-23
栏目:
临床研究
出版日期:
2016-01-13

文章信息/Info

Title:
The Effect of Qing'e Pill on BMD,Bone Metabolic and OPN in Patients with Postmenopausal Osteoporosis
文章编号:
1005-0205(2016)01-0021-03
作者:
余海1; 2 徐晓娟2 沈霖2△ 谢晶2 杨艳萍2 帅波2 周丕琪2
1.四川省成都市第五人民医院(成都,611130)
2.华中科技大学同济医学院附属协和医院
△.通信作者 E-mail:shenlinhb@sina.cn
Author(s):
YU Hai1; 2 XU Xiaojuan2 SHEN Lin2△ XIE Jing2 YANG Yanping2 SHUAI Bo2 ZHOU Piqi2
1.Rehabilitation Department of Chengdu Fifth People's Hospital,Chengdu 611130,China;
2.Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430022,China.
关键词:
青娥丸;  绝经后骨质疏松症;  骨密度;  骨桥蛋白
Keywords:
Qing'e pill;  postmenopausal osteoporosis;  bone mineral density;  osteopontin
分类号:
R274.39
文献标志码:
A
摘要:
目的:观察古方青娥丸对绝经后骨质疏松症患者的临床疗效及骨转换标志物、骨桥蛋白的影响,探讨青娥丸改善绝经后骨质疏松症的作用机制。方法:选择绝经后骨质疏松症患者64例,随机分为青娥丸治疗组(治疗组)及模拟剂治疗组(对照组)治疗6个月。分别在治疗前后检测患者骨密度、骨转换标志物(PINP,S-CTX)、雌激素以及骨桥蛋白的浓度。结果:治疗组在治疗前后骨密度及骨形成标志物PINP、雌激素未见明显变化,骨吸收标志物S-CTX水平显著降低(P<0.05),骨桥蛋白水平亦显著降低(P<0.05); 对照组骨密度持续下降,骨转化标志物及骨桥蛋白、雌激素水平无显著性差异。结论:古方青娥丸能够维持绝经后骨质疏松症患者的骨密度、抑制骨吸收,可能与抑制骨桥蛋白的表达有关。
Abstract:
Objective:To investigate the effect of Chinese herbal Qing'e pill on BMD,Osteopontin(OPN)and bone metabolic for treating the postmenopausal women with osteoporosis,and to explore the mechanism of improving the postmenopausal osteoporosis.Methods: 64 patients with postmenopausal osteoporosis were selected and randomly divided into Qing'e Pill treatment group and placebo control group. The patients in both groups received treatment for 6 months. The BMD,bone turnover markers, estrogen levels, and OPN were detected in each patient at baseline and 6 months after treatment. Results: In Qing'e pill treatment group, there was no significantly increased bone mineral density in either observation period, whereas S-CTX and OPN were decreased after 6 months(P<0.05). However, BMD levels were significantly decreased in observation periods in control group. There was no significant difference in turnover markers, estrogen levels, and OPN, compared with those at the baseline.Conclusion:Qing'e pill is effective on maintaining BMD and inhibiting bone resorption,whith may be related to inhibiting the expression of OPN in patients with postmenopausal osteoporosis.

参考文献/References:

[1] Smith G,Stassen L,Flint S.Treating osteoporosis[J].Ir Med J,2009,102(3):88.
[2] Epstein S.Update of current therapeutic options for the treatment of postmenopausal osteoporosis[J].Clin Ther,2006,28(2):151-173.
[3] 张绍文,李盛华,樊成虎.原发性骨质疏松症的中医辨证诊治进展[J].中国骨质疏松杂志,2013,19(12):1318-1322.
[4] 王金蕴,林燕萍.青娥丸治疗绝经后骨质疏松症的研究进展[J].中国中医骨伤科杂志,2013,21(10):70-72.
[5] 徐晓娟,沈霖,杨艳萍,等.青娥丸对绝经后骨质疏松症患者骨密度和骨转换标志物的影响[J].中国中医骨伤科杂志,2013,21(6):8-10.
[6] Yang YP,Shuai B,Shen L,et al.Effect of Qing'e formula on circulating sclerostin levels in patients with postmenopausal osteoporosis[J].J Huazhong Univ Sci Technolog:Med Sci,2015,35(4):525-530.
[7] 徐颖.青娥丸雌激素样作用及其机理研究[D].上海:上海中医药大学,2010.
[8] Sprini D,Rini GB,Di Stefano L,et al.Correlation between osteoporosis and cardiovascular disease[J].Clin Cases Miner Bone Metab,2014,11(2):117-119.
[9] Wang KX,Denhardt DT.Osteopontin:role in immune regulation and stress responses[J].Cytokine Growth Factor Rev,2008,19(5-6):333-345.
[10] Chang IC,Chiang TI,Yeh KT,et al.Increased serum osteopontin is a risk factor for osteoporosis in menopausal women[J].Osteoporos Int,2010,21(8):1401-1409.
[11] Chen Q,Shou P,Zhang L,et al.An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells [J].Stem Cells,2014,32(2):327-337.
[12] Standal T,Borset M,Sundan A.Role of osteopontin in adhesion,migration,cell survival and bone remodeling[J].Exp Oncol,2004,26(3):179-184.
[13] Fodor D1,Bondor C,Albu A,et al.The value of osteopontin in the assessment of bone mineral density status in postmenopausal women[J].J Investig Med,2013,61(1):15-21.
[14] Chiang TI,Chang IC,Lee HS,et al.Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment[J].Osteoporos Int,2011,22(2):577-585.
[15] Ermakov S,Leonov A,Trofimov S,et al.Quantitative genetic study of the circulating osteopontin in community-selected families[J].Osteoporos Int,2011,22(8):2261-2271.
[16] Altintas A,Saruhan-Direskeneli G,Benbir G,et al.The role of osteopontin:a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? [J].J Neurol Sci,2009,276(1-2):41-44.
[17] Jia P,Li Y,Wang J,et al.The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat[J].Eur J Pharmacol,2012,682(1-3):126-130.
[18] Zhang B,Dai J,Wang H,et al.Anti-osteopontin monoclonal antibody prevents ovariectomy-induced osteoporosis in mice by promotion of osteoclast apoptosis [J].Biochem Biophys Res Commun,2014,452(3):795-800.

备注/Memo

备注/Memo:
收稿日期:2015-07-07
基金项目:国家自然科学基金项目(81473492)
更新日期/Last Update: 2016-01-05